{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:17:16Z","timestamp":1788139036630,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81300959"],"award-info":[{"award-number":["81300959"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program of Guangzhou, China","award":["2014J4100134"],"award-info":[{"award-number":["2014J4100134"]}]},{"name":"Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry","award":["20131792"],"award-info":[{"award-number":["20131792"]}]},{"name":"Chinese National Key Clinical Program in Psychiatry","award":["201202001"],"award-info":[{"award-number":["201202001"]}]},{"name":"Guangzhou Municipal Health Bureau","award":["20131A011091"],"award-info":[{"award-number":["20131A011091"]}]},{"name":"Guangzhou Municipal Key Discipline in Medicine to Guangzhou Brain Hospital","award":["GBH2014-ZD03"],"award-info":[{"award-number":["GBH2014-ZD03"]}]},{"name":"Hongbo He from Chinese National Key Clinical Program in Psychiatry to Guangzhou Brain Hospital","award":["201201001"],"award-info":[{"award-number":["201201001"]}]},{"name":"Guangzhou Municipal Health Bureau","award":["20131A011083"],"award-info":[{"award-number":["20131A011083"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.schres.2015.11.006","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T22:16:49Z","timestamp":1447539409000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Relationship of serum levels of TNF-\u03b1, IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-3174","authenticated-orcid":false,"given":"Ni","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyin","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xini","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2015.11.006_bb0005","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia","volume":"22","author":"Abi-Dargham","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0010","first-page":"7","article-title":"Interleukin 18 in the CNS","volume":"29","author":"Alboni","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.schres.2015.11.006_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/pcn.12089","article-title":"Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia","volume":"68","author":"Altamura","year":"2014","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0020","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1096\/fj.04-1625fje","article-title":"Interleukin-6: a cytokine to forget","volume":"18","author":"Balschun","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.schres.2015.11.006_bb0025","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.biopsych.2012.04.002","article-title":"Tumor necrosis factor gene variation predicts hippocampus volume in healthy individuals","volume":"72","author":"Baune","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0030","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1126\/science.1148045","article-title":"Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase","volume":"318","author":"Behrens","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.schres.2015.11.006_bb0035","doi-asserted-by":"crossref","first-page":"13957","DOI":"10.1523\/JNEUROSCI.4457-08.2008","article-title":"Interleukin-6mediatestheincreaseinNADPH-oxidasein theketaminemodelof schizophrenia","volume":"28","author":"Behrens","year":"2008","journal-title":"J Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia \u2014 a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0050","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.psyneuen.2012.04.001","article-title":"Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome","volume":"37","author":"Beumer","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2015.11.006_bb9000","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jpsychires.2012.08.016","article-title":"Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse","volume":"46","author":"Borovcanin","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.taap.2004.08.011","article-title":"Suppressive effects of ketamine on macrophage functions","volume":"204","author":"Chang","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.schres.2015.11.006_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.taap.2009.06.013","article-title":"Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1b gene expression in lipopolysaccharide- stimulated murine macrophage-like raw 264.7 cells","volume":"40","author":"Chen","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.schres.2015.11.006_bb0065","first-page":"200","article-title":"DSM-IV axle I diagnoses analysis in 506 patients with substance dependence","volume":"18","author":"Chen","year":"2009","journal-title":"Chin. J. Drug Depend."},{"key":"10.1016\/j.schres.2015.11.006_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1213\/00000539-196601000-00007","article-title":"Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581","volume":"45","author":"Corssen","year":"1966","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.schres.2015.11.006_bb0075","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2174\/092986707780597961","article-title":"Microglial activation and its implications in the brain diseases","volume":"14","author":"Dheen","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.schres.2015.11.006_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2013.10.019","article-title":"Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway","volume":"151","author":"Dimitrov","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0085","first-page":"24","article-title":"Notice on further strengthening the management of ketamine released by China Food and Drug Administration","volume":"15","author":"FDA","year":"2004","journal-title":"Capital Med."},{"key":"10.1016\/j.schres.2015.11.006_bb0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.tins.2005.06.008","article-title":"IL-18: a key player in neuroinflammation and neurodegeneration?","volume":"28","author":"Felderhoff-Mueser","year":"2005","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neulet.2011.06.042","article-title":"Increased annexin-V and decreased TNF-\u03b1 serum levels in chronic-medicated patients with schizophrenia","volume":"502","author":"Francesconi","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2015.11.006_bb0100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia","volume":"28","author":"Frohlich","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2015.11.006_bb0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fnsyn.2010.00136","article-title":"Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders","volume":"2","author":"Garay","year":"2010","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jpsychires.2009.10.011","article-title":"Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia","volume":"44","author":"Garc\u00eda-Miss","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2215-0366(15)00098-X","article-title":"D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial","volume":"2","author":"Kantrowitz","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0120","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.neuroscience.2004.03.039","article-title":"Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide syn-thase and cFOS similar to those found in human schizophrenia","volume":"126","author":"Keilhoff","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2015.11.006_bb0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0130","first-page":"268","article-title":"Serum levels of IL-6, IL-10 and TNF-\u03b1 in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance","volume":"33","author":"Kunz","year":"2011","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.schres.2015.11.006_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2015.11.006_bb0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does thePANSSmean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0145","first-page":"280","article-title":"Epidemiological survey of ketamine in China","volume":"14","author":"Lian","year":"2005","journal-title":"Chin. J. Drug Depend."},{"key":"10.1016\/j.schres.2015.11.006_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","article-title":"The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6","volume":"32","author":"Lin","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.schres.2014.09.015","article-title":"Serum levels of TNF-\u03b1, IL-6 and IL-18 elevated in chronic schizophrenic patients","volume":"159","author":"Luo","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00213-014-3650-y","article-title":"Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition","volume":"232","author":"Lv","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2015.11.006_bb0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serumleukemia inhibitory factor receptor","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: a review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.schres.2015.11.006_bb0175","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1749-6632.2000.tb05410.x","article-title":"The immune system and schizophrenia. An integrative view","volume":"917","author":"Muller","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.schres.2015.11.006_bb0180","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1523\/JNEUROSCI.4847-03.2004","article-title":"Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity","volume":"24","author":"Nakajima","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0920-9964(97)00059-5","article-title":"A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?","volume":"26","author":"Naudin","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0190","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/ALN.0b013e31826a0db3","article-title":"Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers","volume":"117","author":"Niesters","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.schres.2015.11.006_bb0195","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biopsych.2006.10.009","article-title":"Tumor necrosis factor-alpha and its inducer inhibit morphine-induced rewarding effects and sensitization","volume":"62","author":"Niwa","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0200","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1742-2094-9-206","article-title":"Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia","volume":"9","author":"Palladino","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.schres.2015.11.006_bb0205","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jpsychires.2012.03.019","article-title":"Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity","volume":"46","author":"Pedrini","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0210","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0215","first-page":"12","article-title":"Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls","volume":"25","author":"Reale","year":"2011","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0220","first-page":"C52","article-title":"Subanesthetic ketamine: how it alters physiology and behavior in humans","volume":"76","author":"Rowland","year":"2005","journal-title":"Aviat. Space Environ. Med."},{"key":"10.1016\/j.schres.2015.11.006_bb0225","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.psychres.2004.04.012","article-title":"Effect of neuroleptic administration on serumlevels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients","volume":"134","author":"Sirota","year":"2005","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0230","doi-asserted-by":"crossref","first-page":"10695","DOI":"10.1523\/JNEUROSCI.2178-07.2007","article-title":"Maternal immune activation alters fetal brain development through interleukin-6","volume":"27","author":"Smith","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0235","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","article-title":"The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia","volume":"65","author":"Song","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0240","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.schres.2013.07.044","article-title":"Elevated levels of adiponectin and other cytokines in drug na\u00efve, first episode schizophrenia patients with normal weight","volume":"150","author":"Song","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0245","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1523\/JNEUROSCI.3376-06.2006","article-title":"Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers","volume":"26","author":"Sparkman","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0250","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0165-1781(00)00196-7","article-title":"Serum interleukin-18 levels are elevated in schizophrenia","volume":"96","author":"Tanaka","year":"2000","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2014.06.012","article-title":"Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia","volume":"54","author":"Tian","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.11.006_bb0260","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1179\/016164105X49463","article-title":"Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge","volume":"27","author":"Tonelli","year":"2005","journal-title":"Neurol. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0265","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.pharmtox.42.082701.160735","article-title":"Glutamatergic mechanisms in schizophrenia","volume":"42","author":"Tsa","year":"2002","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.schres.2015.11.006_bb0270","first-page":"445","article-title":"Epidemiological characteristics of three new drugs abuse in Beijing","volume":"17","author":"Wang","year":"2008","journal-title":"Chin. J. Drug Depend."},{"key":"10.1016\/j.schres.2015.11.006_bb0275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1440-1819.2010.02094.x","article-title":"Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models","volume":"64","author":"Watanabe","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2015.11.006_bb0280","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jpsychires.2012.04.026","article-title":"Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology","volume":"46","author":"Xiu","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2015.11.006_bb0285","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4088\/JCP.v65n0710","article-title":"Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia","volume":"65","author":"Zhang","year":"2004","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415300499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415300499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T04:43:30Z","timestamp":1568954610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996415300499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":58,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0920996415300499"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2015.11.006","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship of serum levels of TNF-\u03b1, IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2015.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}